In males, the incidence-based mortality of NSCLC decreased by 6.3%, while the incidence decreased by 3.1% annually, related mainly to the EGFR first-line therapy introduction in 2013 [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.